GEN Exclusives

More »

GEN News Highlights

More »
Jan 9, 2007

Genentech Procures Amphora Oncology Program

  • Genentech reported that it will purchase Amphora's entire program for an unnamed early-stage oncology target with the potential to treat multiple oncology indications.

    The company thus acquired all the intellectual property for the program, including the preclinical lead and several backup series.

    “Amphora's drug discovery engine has produced and is continuing to produce extremely high quality new products,” points out C. Nicholas Hodge, Ph.D., Amphora's CSO and founder. “Amphora has shown that it is capable of moving programs quickly and cost-effectively from screening to proof-of-concept with surprisingly low attrition rates.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?